

Elisa Callegari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4774723/publications.pdf>

Version: 2024-02-01

33
papers

4,018
citations

304368

22
h-index

433756

31
g-index

33
all docs

33
docs citations

33
times ranked

6089
citing authors

#	ARTICLE	IF	CITATIONS
1	MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i> / <i>TP53</i> Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2020, 80, 1720-1734.	0.4	47
2	Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer. <i>Molecular Oncology</i> , 2020, 14, 2163-2175.	2.1	20
3	Metformin prevents liver tumorigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. <i>Oncogene</i> , 2019, 38, 7035-7045.	2.6	55
4	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 239-250.	2.3	14
5	Animal Models of Hepatocellular Carcinoma Prevention. <i>Cancers</i> , 2019, 11, 1792.	1.7	10
6	MicroRNAs in Animal Models of HCC. <i>Cancers</i> , 2019, 11, 1906.	1.7	25
7	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 485-493.	2.3	81
8	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. <i>Clinical Cancer Research</i> , 2017, 23, 3953-3965.	3.2	137
9	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. <i>Oncogene</i> , 2017, 36, 6617-6626.	2.6	22
10	Over-expression of the <i>miR-483-3p</i> overcomes the <i>miR-145/TP53</i> pro-apoptotic loop in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 31361-31371.	0.8	45
11	Emerging role of microRNAs in the treatment of hepatocellular carcinoma. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2015, , 89.	5.5	0
12	MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. <i>Cell Death and Differentiation</i> , 2015, 22, 46-57.	5.0	140
13	miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the <i>Eμ4-TCL1</i> mouse model. <i>Oncotarget</i> , 2015, 6, 19807-19818.	0.8	29
14	p53/mdm2 Feedback Loop Sustains miR-221 Expression and Dictates the Response to Anticancer Treatments in Hepatocellular Carcinoma. <i>Molecular Cancer Research</i> , 2014, 12, 203-216.	1.5	43
15	Quantification of Circulating miRNAs by Droplet Digital PCR: Comparison of EvaGreen- and TaqMan-Based Chemistries. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2638-2642.	1.1	78
16	Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2014, 7, 43-54.	0.6	34
17	miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. <i>Molecular Cancer</i> , 2013, 12, 130.	7.9	73
18	miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. <i>Frontiers in Genetics</i> , 2013, 4, 64.	1.1	42

#	ARTICLE	IF	CITATIONS
19	Role of microRNAs in hepatocellular carcinoma: a clinical perspective. <i>OncoTargets and Therapy</i> , 2013, 6, 1167.	1.0	56
20	Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus. <i>PLoS ONE</i> , 2013, 8, e73964.	1.1	53
21	Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 927-935.	1.8	9
22	In hepatocellular carcinoma <i>miR-519d</i> is up-regulated by p53 and DNA hypomethylation and targets <i>CDKN1A/p21</i> , <i>PTEN</i> , <i>AKT3</i> and <i>TIMP2</i> . <i>Journal of Pathology</i> , 2012, 227, 275-285.	2.1	180
23	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. <i>Hepatology</i> , 2012, 56, 1025-1033.	3.6	150
24	MicroRNA response to environmental mutagens in liver. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 717, 67-76.	0.4	24
25	Associations of risk factors obesity and occupational airborne exposures with <i>CDKN2A/p16</i> aberrant DNA methylation in esophageal cancer patients. <i>Ecological Management and Restoration</i> , 2010, 23, 597-602.	0.2	13
26	MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly <i>DNMT3A</i> and <i>3B</i> and indirectly <i>DNMT1</i> . <i>Blood</i> , 2009, 113, 6411-6418.	0.6	729
27	MicroRNA involvement in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2189-2204.	1.6	248
28	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 15805-15810.	3.3	1,538
29	Anticancer activity of an adenoviral vector expressing short hairpin RNA against BK virus T-ag. <i>Cancer Gene Therapy</i> , 2007, 14, 297-305.	2.2	7
30	Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA. <i>Gene Therapy</i> , 2007, 14, 459-464.	2.3	22
31	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2006, 18, 209.	1.8	7
32	High-Density Lipoproteins Induce Transforming Growth Factor- β 2 Expression in Endothelial Cells. <i>Circulation</i> , 2005, 111, 2805-2811.	1.6	84
33	Circulating tumor DNAs and non-coding RNAs as potential biomarkers for hepatocellular carcinoma diagnosis, prognosis and response to therapy. <i>Hepatoma Research</i> , 0, 2019, .	0.6	3